TSLA
Tesla
-- 462.280 NVDA
NVIDIA
-- 140.220 PLTR
Palantir
-- 82.380 AMD
Advanced Micro Devices
-- 126.290 MSTR
MicroStrategy
-- 358.180 
Due to Alphamab Oncology's slower growth rate compared to th...
Due to Alphamab Oncology's slower growth rate compared to the industry and notably high P/S ratio, investors may face potential risks. The company's elevated stock price level may not be sustainable in light of its comparatively weak revenue outlook.
What Alphamab Oncology's (HKG:9966) P/S Is Not Telling You
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment